Filing Flows › Maxcyte (MXCT) › Guidance & outlook
Maxcyte (MXCT) guidance and outlook
Maxcyte (MXCT) raised its guidance on Oct 14, 2026: Revenue $34.0M for FY2026.
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $34.0M | raised |
| Revenue | FY2026 | $28.0M | raised |
From the earnings release filed Oct 14, 2026 (8-K on EDGAR).
Maxcyte's latest quarter
Maxcyte, Q2 2026: revenue $7.3M (-14% year over year), operating margin -140.7%, net loss $8.9M, operating cash flow −$4.7M. The chart follows the revenue to costs, profit and cash.
Questions
Did Maxcyte raise or lower its guidance?
Maxcyte (MXCT) raised its guidance on Oct 14, 2026: Revenue $34.0M for FY2026.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.